Bellin Melena D, Kerdsirichairat Tossapol, Beilman Gregory J, Dunn Ty B, Chinnakotla Srinath, Pruett Timothy L, Radosevich David R, Schwarzenberg Sarah J, Sutherland David E R, Arain Mustafa A, Freeman Martin L
Departments of Medicine, Pediatrics, and Surgery, University of Minnesota, Minneapolis, Minnesota.
Departments of Medicine, Pediatrics, and Surgery, University of Minnesota, Minneapolis, Minnesota.
Clin Gastroenterol Hepatol. 2016 Sep;14(9):1317-23. doi: 10.1016/j.cgh.2016.02.027. Epub 2016 Mar 8.
BACKGROUND & AIMS: Therapeutic options are limited for patients with recurrent acute pancreatitis who have intractable symptoms despite maximal endoscopic and medical treatment, but equivocal or no morphologic or functional evidence of chronic pancreatitis. We performed a prospective observational cohort study to determine the efficacy of total pancreatectomy with islet autotransplantation (TPIAT) for these patients.
We collected data from all patients undergoing TPIAT at the University of Minnesota from 2007 through 2013; 49 patients (42 female; mean age, 32.8 ± 7.8 years) had a diagnosis of recurrent acute pancreatitis not provoked by intervention, with negative or equivocal findings from nondiagnostic imaging or pancreatic function tests for chronic pancreatitis, and intractable pain between episodes. Data on insulin use, narcotic requirements, pain scores, and health-related quality of life were collected before TPIAT; 3 months, 6 months, and 1 year afterward; and then yearly.
All 49 patients studied required narcotics before TPIAT (45 daily users and 4 intermittent users); 2 had insulin-treated diabetes. At 1 year after TPIAT, 22 out of 48 patients (46%) reported no use of narcotic pain medications (P < .001 vs baseline). Health-related quality of life score, measured by the physical and mental component summary score, increased by approximately 1 standard deviation from the population mean (P < .001 for the physical component summary; P = .019 for the mental component summary). At 1 year after TPIAT, 21 out of 48 patients (45%) were insulin independent; their mean percent glycosylated hemoglobin A1c at 1 year after TPIAT was 6.0% ± 0.9% (5.2% ± 0.6% pre-TPIAT).
Patients with recurrent acute pancreatitis but lacking clear chronic pancreatitis benefit from TPIAT, with outcomes similar to those previously described for patients with chronic pancreatitis (improved quality of life and reduced narcotic use). For these patients who have otherwise limited surgical treatment options, TPIAT can be considered when medical and endoscopic therapies have failed.
对于复发性急性胰腺炎患者,尽管接受了最大程度的内镜和药物治疗,但仍有顽固性症状,且慢性胰腺炎的形态学或功能证据不明确或不存在,其治疗选择有限。我们进行了一项前瞻性观察队列研究,以确定全胰切除术加胰岛自体移植(TPIAT)对这些患者的疗效。
我们收集了2007年至2013年在明尼苏达大学接受TPIAT的所有患者的数据;49例患者(42例女性;平均年龄32.8±7.8岁)被诊断为非干预诱发的复发性急性胰腺炎,慢性胰腺炎的非诊断性影像学检查或胰腺功能测试结果为阴性或不明确,且发作期间有顽固性疼痛。在TPIAT前、术后3个月、6个月和1年以及之后每年收集胰岛素使用、麻醉剂需求、疼痛评分和健康相关生活质量的数据。
所有49例研究患者在TPIAT前均需要使用麻醉剂(45例每日使用者和4例间歇使用者);2例患有胰岛素治疗的糖尿病。TPIAT后1年,48例患者中有22例(46%)报告未使用麻醉性止痛药(与基线相比,P<.001)。通过身体和心理成分总结评分衡量的健康相关生活质量评分比总体均值增加了约1个标准差(身体成分总结P<.001;心理成分总结P=.019)。TPIAT后1年,48例患者中有21例(45%)不再依赖胰岛素;TPIAT后1年他们的糖化血红蛋白A1c平均百分比为6.0%±0.9%(TPIAT前为5.2%±0.6%)。
复发性急性胰腺炎但缺乏明确慢性胰腺炎的患者可从TPIAT中获益,其结果与先前描述的慢性胰腺炎患者相似(生活质量改善,麻醉剂使用减少)。对于这些手术治疗选择有限的患者,当药物和内镜治疗失败时可考虑TPIAT。